文献速递糖尿病肥胖与代谢综合征

MASLD与MASH的代谢驱动因素:从激素失衡到纤维化

Metabolic drivers of MASLD and MASH: from hormonal imbalance to fibrosis.
PubMed 文献 · Diabetologia · 2026-06-20

本综述整合了代谢功能障碍相关脂肪性肝病(MASLD)及其更严重形式代谢功能障碍相关脂肪性肝炎(MASH)的代谢与激素决定因素,重点阐述胰岛素抵抗、胰岛素与胰高血糖素失衡、脂肪组织功能障碍及肝新生脂肪生成如何通过脂毒性和糖毒性应激、脂肪因子介导的脂肪-肝交互作用、肝星状细胞活化及慢性低度炎症(metaflammation)促进肝损伤与纤维化,并强调性别特异性激素调节和肠-肝-脂肪轴的作用。

要点

  • MASLD/MASH是全身代谢功能障碍的肝脏表现,核心驱动为胰岛素抵抗与关键代谢激素失衡。
  • 胰岛素与胰高血糖素失衡破坏糖脂通量,导致肝脂肪变、糖处理异常及脂毒性/糖毒性应激。
  • 脂肪因子介导的脂肪-肝交互作用激活肝星状细胞和炎症通路,促进纤维化。

核心结论

  • MASLD与MASH是系统性代谢功能障碍的肝脏特异性后果,其进展由胰岛素抵抗、激素失衡及多组织交互驱动。
  • 理解从激素失衡到纤维化的互联机制对识别治疗靶点和推进精准医学至关重要。

研究设计与样本

  • 综述类文章,综合当前关于MASLD进展的代谢与激素决定因素的证据,聚焦多组织系统功能障碍与肝脏炎症、纤维化的机制联系。

主要发现

  • MASLD发病由胰岛素抵抗、糖代谢受损、脂肪组织脂解功能障碍及肝新生脂肪生成改变之间的复杂交互驱动。
  • 胰岛素和胰高血糖素等关键代谢激素失调破坏糖脂通量,导致肝脂肪变、肝糖处理改变、底物递送增加及代谢灵活性降低。
  • 上述代谢紊乱引发脂质蓄积及糖毒性、脂毒性应激,触发肝细胞损伤并激活炎症信号通路。
  • 脂肪因子介导的脂肪组织与肝脏交互作用促进肝星状细胞活化,最终导致慢性低度炎症(metaflammation)和纤维化。
  • 性别特异性激素调节和肠-肝-脂肪轴是疾病异质性和免疫代谢损伤的决定因素。

临床怎么用

  • 临床应关注MASLD/MASH患者的全身代谢紊乱,而非仅局限于肝脏评估。
  • 胰岛素抵抗、糖脂代谢异常及激素失衡可作为疾病进展风险评估的机制性靶点。
  • 考虑性别差异和肠-肝-脂肪轴交互作用对疾病异质性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe and aggressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent liver-specific consequences of systemic metabolic dysfunction. This review synthesises current evidence on the metabolic and hormonal determinants of MASLD progression, with a particular focus on the mechanisms linking systemic dysfunction across multiple tissues to hepatic inflammation and fibrosis. MASLD pathogenesis is driven by complex interactions between insulin resistance, impaired glucose metabolism, dysfunctional adipose tissue lipolysis and altered hepatic de novo lipogenesis. Central to this process is the dysregulation of key metabolic hormones, including insulin and glucagon, whose imbalance disrupts both glucose and lipid fluxes, leading not only to hepatic steatosis but also to altered hepatic glucose handling, increased substrate delivery and reduced metabolic flexibility. This promotes lipid accumulation as well as glucotoxic and lipotoxic stress. These metabolic disturbances trigger hepatocellular injury and activate inflammatory signalling pathways, including adipokine-mediated crosstalk between adipose tissue and the liver, promoting hepatic stellate cell activation and ultimately leading to a state of chronic low-grade inflammation (metaflammation) that integrates hepatocyte stress, immune cell activation and hepatic stellate cell-driven fibrogenesis. This review also highlights sex-specific hormonal regulation and the gut-liver-adipose axis as determinants of disease heterogeneity and immunometabolic injury. By integrating mechanistic insights across glucose and lipid metabolism, tissues and hormonal pathways, this review underscores how systemic metabolic dysfunction is translated into progressive liver injury and fibrosis. Understanding these interconnected mechanisms of disease progression is essential for identifying therapeutic targets and advancing mechanism-based and precision medicine approaches for MASLD and MASH.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Gastaldelli A, Scoditti E, Macedo MP, et al. Metabolic drivers of MASLD and MASH: from hormonal imbalance to fibrosis. Diabetologia. 2026. PMID: 42322377. doi:10.1007/s00125-026-06774-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。